Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
|Videos|July 7, 2016
Natural Language Processing in Diagnosis of Lung Cancer
Author(s)Melissa Johnson, MD
Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the use of natural language processing in the diagnosis of lung cancer.
Advertisement
Advertisement
Related to this article
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Status to LYT-200 Combo in High-Risk MDS
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Looking Back on the Transformation of CLL Treatment: Jeff Sharman, MD
4
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
5